{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:42:33Z","timestamp":1786196553400,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005639","name":"Universidade De S\u00e3o Paulo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) remains one of the most aggressive and lethal malignancies, with clinical outcomes under the standard-of-care Stupp protocol remaining suboptimal. While oncolytic virus (OV) therapy has emerged as a mechanistically distinct and promising approach, its clinical success is frequently hindered by profound intratumoral heterogeneity and emerging resistance. This critical review proposes that the efficacy of virotherapy may be meaningfully enhanced by integrating circadian biology into treatment schedules; a paradigm termed \u201cOncolytic Chronovirotherapy.\u201d Recent evidence demonstrates that the infection cycle of neurotropic viruses, which serve as the scaffold for many OVs, is not a static process but is inherently regulated by the host\u2019s circadian clock. Fundamental studies reveal that the expression of essential viral entry receptors, such as Nectin-1 (for HSV-1) and p75NTR, exhibits robust circadian oscillations directly coordinated by the core molecular clock, specifically the BMAL1\/CLOCK complex. Furthermore, the tumor immune microenvironment and cellular vulnerability to adjuvant chemotherapy (temozolomide) show synchronized peaks of activity, typically concentrated during the morning window, which often coincides with the nadir of DNA repair enzymes like MGMT. We argue that synchronizing OV administration with these windows of maximal receptor density and robust immune surveillance may maximize tumor lysis and facilitate the conversion of \u201ccold\u201d tumors into \u201chot,\u201d immune-responsive environments. The utilization of personalized circadian biomarkers and mathematical modeling to guide therapy delivery will be essential for the next generation of precision neuro-oncology.<\/jats:p>","DOI":"10.1007\/s13365-026-01325-7","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:01:26Z","timestamp":1783346486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circadian-guided oncolytic virotherapy for glioblastoma"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-1477","authenticated-orcid":false,"given":"Alexandro","family":"Guterres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"1325_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/ijc.35234","volume":"156","author":"M Abusamak","year":"2025","unstructured":"Abusamak M, Abu-Samak A, Cai W et al (2025) Chronotherapy in head and neck cancer: A systematic review and meta\u2010analysis. Int J Cancer 156:1015\u20131032. https:\/\/doi.org\/10.1002\/ijc.35234","journal-title":"Int J Cancer"},{"key":"1325_CR2","doi-asserted-by":"publisher","unstructured":"Albaqami A (2025) Unravelling the link between circadian clock genes and brain tumors: From pathological disruptions to potential therapeutic interventions. Front Pharmacol 16. https:\/\/doi.org\/10.3389\/fphar.2025.1617713","DOI":"10.3389\/fphar.2025.1617713"},{"key":"1325_CR3","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.3390\/cancers14205071","volume":"14","author":"A Amiama-Roig","year":"2022","unstructured":"Amiama-Roig A, Verdugo-Sivianes EM, Carnero A, Blanco J-R (2022) Chronotherapy: Circadian Rhythms and Their Influence in Cancer Therapy. Cancers (Basel) 14:5071. https:\/\/doi.org\/10.3390\/cancers14205071","journal-title":"Cancers (Basel)"},{"key":"1325_CR4","doi-asserted-by":"publisher","unstructured":"Arafa K, Emara M (2020) Insights About Circadian Clock and Molecular Pathogenesis in Gliomas. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.00199","DOI":"10.3389\/fonc.2020.00199"},{"key":"1325_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1582-4934.2003.tb00243.x","volume":"7","author":"C Badiu","year":"2003","unstructured":"Badiu C (2003) Genetic clock of biologic rhythms. J Cell Mol Med 7:408\u2013416. https:\/\/doi.org\/10.1111\/j.1582-4934.2003.tb00243.x","journal-title":"J Cell Mol Med"},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0748730420967768","volume":"36","author":"H Borrmann","year":"2021","unstructured":"Borrmann H, McKeating JA, Zhuang X (2021) The Circadian Clock and Viral Infections. J Biol Rhythms 36:9\u201322. https:\/\/doi.org\/10.1177\/0748730420967768","journal-title":"J Biol Rhythms"},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7785\/tcrt.2012.500250","volume":"12","author":"Z Chen","year":"2013","unstructured":"Chen Z, Liu P, Li C et al (2013) Deregulated Expression of the Clock Genes in Gliomas. Technol Cancer Res Treat 12:91\u201397. https:\/\/doi.org\/10.7785\/tcrt.2012.500250","journal-title":"Technol Cancer Res Treat"},{"key":"1325_CR8","doi-asserted-by":"publisher","unstructured":"Coates K, Nibbs RJ, Fraser AR (2024) Going viral: targeting glioblastoma using oncolytic viruses. https:\/\/doi.org\/10.1093\/immadv\/ltaf024. Immunotherapy Advances 5:","DOI":"10.1093\/immadv\/ltaf024"},{"key":"1325_CR9","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1530\/JME-19-0153","volume":"63","author":"KH Cox","year":"2019","unstructured":"Cox KH, Takahashi JS (2019) Circadian clock genes and the transcriptional architecture of the clock mechanism. J Mol Endocrinol 63:R93\u2013R102. https:\/\/doi.org\/10.1530\/JME-19-0153","journal-title":"J Mol Endocrinol"},{"key":"1325_CR10","doi-asserted-by":"publisher","unstructured":"Damato AR, Luo J, Katumba RGN et al (2021) Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study. https:\/\/doi.org\/10.1093\/noajnl\/vdab041. Neurooncol Adv 3:","DOI":"10.1093\/noajnl\/vdab041"},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.3390\/cancers13112756","volume":"13","author":"J De La Cruz Minyety","year":"2021","unstructured":"De La Cruz Minyety J, Shuboni-Mulligan DD, Briceno N et al (2021) Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. Cancers (Basel) 13:2756. https:\/\/doi.org\/10.3390\/cancers13112756","journal-title":"Cancers (Basel)"},{"key":"1325_CR12","doi-asserted-by":"publisher","unstructured":"Diallo AB, Coiffard B, Leone M et al (2020) For Whom the Clock Ticks: Clinical Chronobiology for Infectious Diseases. Front Immunol 11. https:\/\/doi.org\/10.3389\/fimmu.2020.01457","DOI":"10.3389\/fimmu.2020.01457"},{"key":"1325_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12672-024-01643-4","volume":"15","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Rabbani SA, Ali AA et al (2024) Circadian rhythms and cancer: implications for timing in therapy. Discover Oncol 15:767. https:\/\/doi.org\/10.1007\/s12672-024-01643-4","journal-title":"Discover Oncol"},{"key":"1325_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41392-022-00899-y","volume":"7","author":"F Fagiani","year":"2022","unstructured":"Fagiani F, Di Marino D, Romagnoli A et al (2022) Molecular regulations of circadian rhythm and implications for physiology and diseases. Signal Transduct Target Ther 7:41. https:\/\/doi.org\/10.1038\/s41392-022-00899-y","journal-title":"Signal Transduct Target Ther"},{"key":"1325_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","volume":"15","author":"E Galanis","year":"2024","unstructured":"Galanis E, Dooley KE, Keith Anderson S et al (2024) Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial. Nat Commun 15:493. https:\/\/doi.org\/10.1038\/s41467-023-43076-7","journal-title":"Nat Commun"},{"key":"1325_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ccell.2024.11.012","volume":"43","author":"MF Gonzalez-Aponte","year":"2025","unstructured":"Gonzalez-Aponte MF, Damato AR, Simon T et al (2025) Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host. Cancer Cell 43:144\u2013160e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.11.012","journal-title":"Cancer Cell"},{"key":"1325_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11060-025-05242-3","volume":"176","author":"MF Gonzalez-Aponte","year":"2026","unstructured":"Gonzalez-Aponte MF, Huang Y, Leidig WA et al (2026) Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma. J Neurooncol 176:36. https:\/\/doi.org\/10.1007\/s11060-025-05242-3","journal-title":"J Neurooncol"},{"key":"1325_CR18","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1073\/pnas.1915773117","volume":"117","author":"EN Greenberg","year":"2020","unstructured":"Greenberg EN, Marshall ME, Jin S et al (2020) Circadian control of interferon-sensitive gene expression in murine skin. Proc Natl Acad Sci 117:5761\u20135771. https:\/\/doi.org\/10.1073\/pnas.1915773117","journal-title":"Proc Natl Acad Sci"},{"key":"1325_CR19","doi-asserted-by":"publisher","unstructured":"Hu M, Liao X, Tao Y, Chen Y (2023) Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1285113","DOI":"10.3389\/fimmu.2023.1285113"},{"key":"1325_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12935-019-1023-7","volume":"19","author":"Z Huang","year":"2019","unstructured":"Huang Z, Zhao X, Wu X et al (2019) LncRNA UCA1 facilitated cell growth and invasion through the miR-206\/CLOCK axis in glioma. Cancer Cell Int 19:316. https:\/\/doi.org\/10.1186\/s12935-019-1023-7","journal-title":"Cancer Cell Int"},{"key":"1325_CR20","doi-asserted-by":"publisher","first-page":"105607","DOI":"10.1016\/j.ebiom.2025.105607","volume":"113","author":"Z Huang","year":"2025","unstructured":"Huang Z, Karabou\u00e9 A, Zeng L et al (2025) Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study. EBioMedicine 113:105607. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105607","journal-title":"EBioMedicine"},{"key":"1325_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.molcel.2016.10.012","volume":"64","author":"A-L Huber","year":"2016","unstructured":"Huber A-L, Papp SJ, Chan AB et al (2016) CRY2 and FBXL3 Cooperatively Degrade c-MYC. Mol Cell 64:774\u2013789. https:\/\/doi.org\/10.1016\/j.molcel.2016.10.012","journal-title":"Mol Cell"},{"key":"1325_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3892\/or.2013.2381","volume":"29","author":"EM JUNG C-H, KIM","year":"2013","unstructured":"JUNG C-H, KIM EM, PARK JK et al (2013) Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep 29:2109\u20132113. https:\/\/doi.org\/10.3892\/or.2013.2381","journal-title":"Oncol Rep"},{"key":"1325_CR24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.4161\/cc.8.11.8707","volume":"8","author":"T-H Kang","year":"2009","unstructured":"Kang T-H, Sancar A (2009) Circadian regulation of DNA excision repair: Implications for chrono-chemotherapy. Cell Cycle 8:1665\u20131667. https:\/\/doi.org\/10.4161\/cc.8.11.8707","journal-title":"Cell Cycle"},{"key":"1325_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41416-024-02704-9","volume":"131","author":"A Karabou\u00e9","year":"2024","unstructured":"Karabou\u00e9 A, Innominato PF, Wreglesworth NI et al (2024) Why does circadian timing of administration matter for immune checkpoint inhibitors\u2019 efficacy? Br J Cancer 131:783\u2013796. https:\/\/doi.org\/10.1038\/s41416-024-02704-9","journal-title":"Br J Cancer"},{"key":"1325_CR26","doi-asserted-by":"publisher","unstructured":"Kisamore CO, Elliott BD, DeVries AC et al (2023) Chronotherapeutics for Solid Tumors. Pharmaceutics 15:2023. https:\/\/doi.org\/10.3390\/pharmaceutics15082023","DOI":"10.3390\/pharmaceutics15082023"},{"key":"1325_CR27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C et al (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419\u20131427. https:\/\/doi.org\/10.1200\/JCO.2017.75.8219","journal-title":"J Clin Oncol"},{"key":"1325_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-pharmtox-051920-095416","volume":"64","author":"FA L\u00e9vi","year":"2024","unstructured":"L\u00e9vi FA, Okyar A, Hadadi E et al (2024) Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy. Annu Rev Pharmacol Toxicol 64:89\u2013114. https:\/\/doi.org\/10.1146\/annurev-pharmtox-051920-095416","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1325_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1158\/1535-7163.MCT-05-0332","volume":"5","author":"X-M Li","year":"2006","unstructured":"Li X-M, Kanekal S, Cr\u00e9pin D et al (2006) Circadian pharmacology of <\u2009scp>l -alanosine (SDX-102) in mice. Mol Cancer Ther 5:337\u2013346. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0332","journal-title":"Mol Cancer Ther"},{"key":"1325_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling AL, Solomon IH, Landivar AM et al (2023) Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623:157\u2013166. https:\/\/doi.org\/10.1038\/s41586-023-06623-2","journal-title":"Nature"},{"key":"1325_CR31","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.3390\/cancers13215268","volume":"13","author":"AV Lipatova","year":"2021","unstructured":"Lipatova AV, Soboleva AV, Gorshkov VA et al (2021) Multi-Omics Analysis of Glioblastoma Cells\u2019 Sensitivity to Oncolytic Viruses. Cancers (Basel) 13:5268. https:\/\/doi.org\/10.3390\/cancers13215268","journal-title":"Cancers (Basel)"},{"key":"1325_CR33","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.3390\/cancers17243948","volume":"17","author":"J Liu","year":"2025","unstructured":"Liu J, Wang Y, Su S et al (2025) Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions. Cancers (Basel) 17:3948. https:\/\/doi.org\/10.3390\/cancers17243948","journal-title":"Cancers (Basel)"},{"key":"1325_CR32","doi-asserted-by":"publisher","unstructured":"Liu D, Li Z, Cui H et al (2026) Chrono-immunotherapy\u2019s current and future optimization strategies: immunotherapy timing in line with the circadian rhythm brings longer survival benefits. Front Immunol 17. https:\/\/doi.org\/10.3389\/fimmu.2026.1777437","DOI":"10.3389\/fimmu.2026.1777437"},{"key":"1325_CR34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev.genom.5.061903.175925","volume":"5","author":"PL Lowrey","year":"2004","unstructured":"Lowrey PL, Takahashi JS (2004) MAMMALIAN CIRCADIAN BIOLOGY: Elucidating Genome-Wide Levels of Temporal Organization. Annu Rev Genomics Hum Genet 5:407\u2013441. https:\/\/doi.org\/10.1146\/annurev.genom.5.061903.175925","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1325_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1515\/revneuro-2018-0041","volume":"30","author":"S Maitra","year":"2019","unstructured":"Maitra S, Bhattacharya D, Das S, Bhattacharya S (2019) Melatonin and its anti-glioma functions: a comprehensive review. Rev Neurosci 30:527\u2013541. https:\/\/doi.org\/10.1515\/revneuro-2018-0041","journal-title":"Rev Neurosci"},{"key":"1325_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jid.2017.07.838","volume":"138","author":"T Matsuzawa","year":"2018","unstructured":"Matsuzawa T, Nakamura Y, Ogawa Y et al (2018) Differential Day-Night Outcome to HSV-2 Cutaneous Infection. J Invest Dermatology 138:233\u2013236. https:\/\/doi.org\/10.1016\/j.jid.2017.07.838","journal-title":"J Invest Dermatology"},{"key":"1325_CR37","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.3390\/ijms25115846","volume":"25","author":"C Munteanu","year":"2024","unstructured":"Munteanu C, Turti S, Achim L et al (2024) The Relationship between Circadian Rhythm and Cancer Disease. Int J Mol Sci 25:5846. https:\/\/doi.org\/10.3390\/ijms25115846","journal-title":"Int J Mol Sci"},{"key":"1325_CR38","doi-asserted-by":"publisher","unstructured":"Nagy S, Hussein A, Kesselman MM (2025) The Importance of Timing in Immunotherapy: A Systematic Review. Cureus. https:\/\/doi.org\/10.7759\/cureus.82994","DOI":"10.7759\/cureus.82994"},{"key":"1325_CR39","doi-asserted-by":"publisher","unstructured":"Nair S, Mazzoccoli L, Jash A et al (2021) Zika virus oncolytic activity requires CD8\u2009+\u2009T cells and is boosted by immune checkpoint blockade. JCI Insight 6. https:\/\/doi.org\/10.1172\/jci.insight.144619","DOI":"10.1172\/jci.insight.144619"},{"key":"1325_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41698-024-00530-z","volume":"8","author":"N Nelson","year":"2024","unstructured":"Nelson N, Rel\u00f3gio A (2024) Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock. NPJ Precis Oncol 8:40. https:\/\/doi.org\/10.1038\/s41698-024-00530-z","journal-title":"NPJ Precis Oncol"},{"key":"1325_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41698-025-01205-z","volume":"10","author":"N Nelson","year":"2025","unstructured":"Nelson N, Zimmer O, Rel\u00f3gio A (2025) Personalized chronotherapy in glioblastoma: integrating circadian profiling and PK\u2013PD modelling to optimize temozolomide timing. NPJ Precis Oncol 10:17. https:\/\/doi.org\/10.1038\/s41698-025-01205-z","journal-title":"NPJ Precis Oncol"},{"key":"1325_CR42","doi-asserted-by":"publisher","first-page":"32010","DOI":"10.1038\/s41598-025-17461-9","volume":"15","author":"EA Nettnin","year":"2025","unstructured":"Nettnin EA, Garcia CA, Sayed FF et al (2025) Circadian rhythms in pediatric high-grade gliomas may contribute to treatment efficacy. Sci Rep 15:32010. https:\/\/doi.org\/10.1038\/s41598-025-17461-9","journal-title":"Sci Rep"},{"key":"1325_CR43","doi-asserted-by":"publisher","first-page":"e010644","DOI":"10.1136\/jitc-2024-010644","volume":"13","author":"BC \u00d6zdemir","year":"2025","unstructured":"\u00d6zdemir BC, Bill R, Okyar A et al (2025) Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials. J Immunother Cancer 13:e010644. https:\/\/doi.org\/10.1136\/jitc-2024-010644","journal-title":"J Immunother Cancer"},{"key":"1325_CR44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12920-023-01585-w","volume":"16","author":"M Petkovic","year":"2023","unstructured":"Petkovic M, Yal\u00e7in M, Heese O, Rel\u00f3gio A (2023) Differential expression of the circadian clock network correlates with tumour progression in gliomas. BMC Med Genomics 16:154. https:\/\/doi.org\/10.1186\/s12920-023-01585-w","journal-title":"BMC Med Genomics"},{"key":"1325_CR45","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","volume":"22","author":"DC Qian","year":"2021","unstructured":"Qian DC, Kleber T, Brammer B et al (2021) Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol 22:1777\u20131786. https:\/\/doi.org\/10.1016\/S1470-2045(21)00546-5","journal-title":"Lancet Oncol"},{"key":"1325_CR46","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1186\/s12967-024-05650-5","volume":"22","author":"A Reale","year":"2024","unstructured":"Reale A, Gatta A, Shaik AKB et al (2024) An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma. J Transl Med 22:862. https:\/\/doi.org\/10.1186\/s12967-024-05650-5","journal-title":"J Transl Med"},{"key":"1325_CR47","doi-asserted-by":"publisher","unstructured":"Sancar A, Van Gelder RN (2021) Clocks, cancer, and chronochemotherapy. Science (1979) 371:. https:\/\/doi.org\/10.1126\/science.abb0738","DOI":"10.1126\/science.abb0738"},{"key":"1325_CR48","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.ebiom.2024.105219","volume":"105","author":"TE Sch\u00e4fer","year":"2024","unstructured":"Sch\u00e4fer TE, Knol LI, Haas FV et al (2024) Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. EBioMedicine 105:105219. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105219","journal-title":"EBioMedicine"},{"key":"1325_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41419-025-08363-9","volume":"17","author":"MM Shamekh","year":"2025","unstructured":"Shamekh MM, Lindqvist B, Nalvarte I (2025) Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness. Cell Death Dis 17:114. https:\/\/doi.org\/10.1038\/s41419-025-08363-9","journal-title":"Cell Death Dis"},{"key":"1325_CR50","doi-asserted-by":"publisher","unstructured":"Sharma P, Aaroe A, Liang J, Puduvalli VK (2023) Tumor microenvironment in glioblastoma: Current and emerging concepts. https:\/\/doi.org\/10.1093\/noajnl\/vdad009. Neurooncol Adv 5:","DOI":"10.1093\/noajnl\/vdad009"},{"key":"1325_CR51","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/cancers13040614","volume":"13","author":"E Stavrakaki","year":"2021","unstructured":"Stavrakaki E, Dirven CMF, Lamfers MLM (2021) Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response. Cancers (Basel) 13:614. https:\/\/doi.org\/10.3390\/cancers13040614","journal-title":"Cancers (Basel)"},{"key":"1325_CR52","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA 314:2535. https:\/\/doi.org\/10.1001\/jama.2015.16669","journal-title":"JAMA"},{"key":"1325_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MTY, Panda S (2019) Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment. Trends Cancer 5:475\u2013494. https:\/\/doi.org\/10.1016\/j.trecan.2019.07.002","journal-title":"Trends Cancer"},{"key":"1325_CR54","doi-asserted-by":"publisher","unstructured":"Swildens KX, Sillevis Smitt PAE, van den Bent MJ et al (2022) The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. Neurooncol Adv 4. https:\/\/doi.org\/10.1093\/noajnl\/vdac087","DOI":"10.1093\/noajnl\/vdac087"},{"key":"1325_CR55","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrg.2016.150","volume":"18","author":"JS Takahashi","year":"2017","unstructured":"Takahashi JS (2017) Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet 18:164\u2013179. https:\/\/doi.org\/10.1038\/nrg.2016.150","journal-title":"Nat Rev Genet"},{"key":"1325_CR56","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12985-025-02936-y","volume":"22","author":"J Tang","year":"2025","unstructured":"Tang J, Pan M, Liu J et al (2025) Circadian clock proteins BMAL1 and CLOCK regulate HSV-1 entry into nerve cells through NECTIN-1. Virol J 22:333. https:\/\/doi.org\/10.1186\/s12985-025-02936-y","journal-title":"Virol J"},{"key":"1325_CR57","doi-asserted-by":"publisher","first-page":"8596","DOI":"10.1021\/acs.jmedchem.1c01946","volume":"65","author":"A Thakur","year":"2022","unstructured":"Thakur A, Faujdar C, Sharma R et al (2022) Glioblastoma: Current Status, Emerging Targets, and Recent Advances. J Med Chem 65:8596\u20138685. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01946","journal-title":"J Med Chem"},{"key":"1325_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L (2022) Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther 7:117. https:\/\/doi.org\/10.1038\/s41392-022-00951-x","journal-title":"Signal Transduct Target Ther"},{"key":"1325_CR59","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y et al (2022) Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28:1630\u20131639. https:\/\/doi.org\/10.1038\/s41591-022-01897-x","journal-title":"Nat Med"},{"key":"1325_CR60","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.3390\/ijms26125873","volume":"26","author":"F Wan","year":"2025","unstructured":"Wan F, Zhang Z, Zhang J et al (2025) The Circadian Rhythm Gene Network Could Distinguish Molecular Profile and Prognosis for Glioblastoma. Int J Mol Sci 26:5873. https:\/\/doi.org\/10.3390\/ijms26125873","journal-title":"Int J Mol Sci"},{"key":"1325_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5612","volume":"56","author":"J Xu","year":"2025","unstructured":"Xu J, Xia Z, Wang S, Xia Q (2025) Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review). Int J Mol Med 56:1\u201327. https:\/\/doi.org\/10.3892\/ijmm.2025.5612","journal-title":"Int J Mol Med"},{"key":"1325_CR62","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3390\/cancers17193180","volume":"17","author":"R Yang","year":"2025","unstructured":"Yang R, Hedberg J, Montagano J et al (2025) Oncolytic Virus Therapies in Malignant Gliomas: Advances and Clinical Trials. Cancers (Basel) 17:3180. https:\/\/doi.org\/10.3390\/cancers17193180","journal-title":"Cancers (Basel)"},{"key":"1325_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41421-026-00867-8","volume":"12","author":"S Zeng","year":"2026","unstructured":"Zeng S, Zhang Q, Yang X et al (2026) Chronobiology of neurotropic viruses: rhythmic viral entry and arrhythmic host clocks. Cell Discov 12:11. https:\/\/doi.org\/10.1038\/s41421-026-00867-8","journal-title":"Cell Discov"},{"key":"1325_CR64","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1080\/21655979.2021.1947075","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang C, Xu J, Chen L, Lin X (2021) Multi-omics landscape of circadian rhythm pathway alterations in Glioma. Bioengineered 12:3294\u20133308. https:\/\/doi.org\/10.1080\/21655979.2021.1947075","journal-title":"Bioengineered"},{"key":"1325_CR65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1245\/s10434-025-18315-4","volume":"33","author":"F Zhang","year":"2026","unstructured":"Zhang F, Chen M, Hu S et al (2026) Circadian Rhythms in Cancer: Mechanistic Insights, Chronotherapeutic Strategies, and Translational Challenges. Ann Surg Oncol 33:296\u2013308. https:\/\/doi.org\/10.1245\/s10434-025-18315-4","journal-title":"Ann Surg Oncol"},{"key":"1325_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-022-01238-y","volume":"15","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhang Z, Nice E et al (2022) Circadian rhythms and cancers: the intrinsic links and therapeutic potentials. J Hematol Oncol 15:21. https:\/\/doi.org\/10.1186\/s13045-022-01238-y","journal-title":"J Hematol Oncol"},{"key":"1325_CR67","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00281-021-00908-2","volume":"44","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, Edgar RS, McKeating JA (2022) The role of circadian clock pathways in viral replication. Semin Immunopathol 44:175\u2013182. https:\/\/doi.org\/10.1007\/s00281-021-00908-2","journal-title":"Semin Immunopathol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-026-01325-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:51:19Z","timestamp":1786193479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-026-01325-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1007\/s13365-026-01325-7","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests. Dr. Guterres has received research funding unrelated to this work.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24"}}